DTMC

Studies associated with:

Division of Therapeutics and Medical Consequences

Division Study Number Title Investigator(s) Release Date
DTMC NIDA-CPU-0005 Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0004 Study of Interactions Between GBR 12909 and Cocaine Kathryn Cunningham, Ph.D., John Grabowski, Ph.D.
DTMC NIDA-CPU-0006 A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine Reese Jones, M.D.
DTMC NIDA-CPU-0003 Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0002 Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CTO-0006 Cocaine-Metyrapone Interaction Study Bonita Singal, M.D., Theresa Winhusen, Ph.D.
DTMC NIDA-CTO-0005 Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence John D. Roache, Ph.D.
DTMC NIDA-CTO-0004 Assessment Of Potential Interactions Between Intravenous Methamphetamine And Oral Selegiline Thomas F. Newton, M.D.
DTMC NIDA-CTO-0003 Assessment Of Potential Interactions Between Intravenous Cocaine And Tolcapone Thomas F. Newton, M.D.
DTMC NIDA-CTO-0002 Safety Evaluation Of Cocaine Treatment Medication, Modafinil: Interactions With Intravenous Cocaine Robert J. Malcolm, M.D., C. Lindsay DeVane, Pharm.D.
DTMC NIDA-MDS-0007 Phase 2, Double-Blind, Placebo-Controlled Trial Of Bupropion For Methamphetamine Dependence Ann Anderson, M.D.
DTMC NIDA-MDS-0004 Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For The Treatment Of Cocaine Dependence Domenic Ciraulo, M.D.
DTMC NIDA-CTO-0001 Phase 2, Double-Blind, Placebo-Controlled Trial Of Reserpine For The Treatment Of Cocaine Dependence Eugene Somoza, M.D.
DTMC NIDA-CSP-1026 Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For Methamphetamine Dependence Ahmed Elkashef, M.D.
DTMC NIDA-CSP-1025 Phase 2, Double-Blind, Placebo-Controlled Trial Of Topiramate For The Treatment Of Methamphetamine Dependence Bankole Johnson, DSc., M.D., Ph.D.
DTMC NIDA-CSP-1018 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Walter Ling, M.D., Paul J. Fudala, Ph.D., Paul Casadonte, M.D.
DTMC NIDA-CSP-1008B A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Peter Bridge, M.D.
DTMC NIDA-CSP-1008A A Multicenter Efficacy/Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Peter Bridge, M.D., Paul J. Fudala, Ph.D.
DTMC NIDA-CSP-999 A Multicenter Clinical Trial of Buprenorphine in Treatment of Opiate Dependence Walter Ling, M.D., Donald R. Wesson, M.D., C. James Klett, Ph.D.
DTMC NIDA-CPU-0016 Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Methamphetamine And Osmotic-Release Methylphenidate (Oros-Mph) Eugene Somoza, M.D.